In December 2024, global markets are navigating a complex landscape with the Nasdaq Composite reaching new heights, while small-cap stocks face challenges as evidenced by the Russell 2000’s underperformance against larger indices. Amidst expectations of an imminent Federal Reserve rate cut and a cooling labor market, investors are keenly observing high-growth tech stocks that demonstrate resilience and potential in this dynamic environment.
|
Name |
Revenue Growth |
Earnings Growth |
Growth Rating |
|---|---|---|---|
|
Material Group |
20.45% |
24.01% |
★★★★★★ |
|
Yggdrazil Group |
30.20% |
87.10% |
★★★★★★ |
|
Seojin SystemLtd |
35.41% |
39.86% |
★★★★★★ |
|
eWeLLLtd |
27.24% |
28.74% |
★★★★★★ |
|
Ascelia Pharma |
76.15% |
47.16% |
★★★★★★ |
|
Medley |
25.57% |
31.67% |
★★★★★★ |
|
Waystream Holding |
22.09% |
113.25% |
★★★★★★ |
|
Mental Health TechnologiesLtd |
25.83% |
113.12% |
★★★★★★ |
|
Fine M-TecLTD |
36.52% |
131.08% |
★★★★★★ |
|
JNTC |
29.48% |
104.37% |
★★★★★★ |
Click here to see the full list of 1249 stocks from our High Growth Tech and AI Stocks screener.
Let’s explore several standout options from the results in the screener.
Simply Wall St Growth Rating: ★★★★★★
Overview: Bioneer Corporation is a biotechnology company with operations in South Korea and internationally, holding a market cap of ₩518.79 billion.
Operations: Bioneer Corporation generates revenue through its biotechnology operations across various regions, including South Korea, the Americas, Europe, Asia, and Africa.
Bioneer, despite recent setbacks with a net loss reported in the third quarter of 2024, shows promise with an expected revenue growth of 26.1% per year, outpacing the South Korean market average of 9%. This growth is complemented by an anticipated shift to profitability within three years, showcasing potential resilience and adaptability in its operational strategy. The company’s commitment to enhancing corporate value was evident from special calls held in December 2024 aimed at deepening stakeholder understanding of its business model. With R&D expenses not specified but integral to its recovery and future profitability, Bioneer appears poised for a turnaround bolstered by strategic planning and market foresight.
-
Click here and access our complete health analysis report to understand the dynamics of Bioneer.
-
Evaluate Bioneer’s historical performance by accessing our past performance report.
Simply Wall St Growth Rating: ★★★★★☆
Overview: EuBiologics Co., Ltd. is a biopharmaceutical company that develops vaccines for epidemics in South Korea and has a market cap of approximately ₩465.08 billion.
Operations: EuBiologics generates revenue primarily from its pharmaceuticals segment, which amounts to approximately ₩69.37 billion.
